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In Alzheimer’s disease (AD), tau hyperphosphorylation and neuroﬁbrillary tangle (NFT) for-
mation are strongly associated with dementia, a characteristic and early feature of this
disease. Glycogen synthase kinase 3β (GSK-3β) is a pivotal kinase in both the normal
and pathological phosphorylation of tau. In the diseased state, hyperphosphorylated tau is
deposited in NFTs, the formation of which, drive the disease process. GSK-3β which is also
involved in long-term depression induction, interacts with tau to inhibit synaptic long-term
potentiation. Strong lines of evidence suggest that the activation of GSK-3β is responsible
for the memory deﬁcits seen in both advanced age and AD. In this review, we will focus on
the role of GSK-3β in brain function, particularly in memory maintenance.We will examine
human and mouse studies which suggest a role for GSK-3β in memory maintenance and
the eventual development of memory deﬁcits.
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ALZHEIMER’S DISEASE AND MEMORY
Memory impairment in old age is a hallmark of the initial stage
of Alzheimer’s disease (AD), with dementia developing in the
ﬁnal stages (Poissonnet etal., 2012). AD is characterized by the
extensive deposition of amyloid β (Aβ), outside of neurons,
and the formation of neuroﬁbrillary tangles (NFTs) consisting
of hyperphosphorylated tau, as intraneuronal inclusions (Selkoe,
1986). The relationship between the clinical course of AD and
the observed pathological changes is not yet fully understood.
Genetic studies of familial AD identiﬁed three causative genes,
APP,PSEN 1, and PSEN 2 (Tandon etal., 2000). Since these genes
formpartofacascadethatresultsinAβgeneration,theAβhypoth-
esis emerged as a mechanism forAD pathophysiology (Hardy and
Selkoe,2002). ThistheorystatesthatAβdepositiondirectlyaffects
neurons,inducing NFTs and neuronal death,leading to dementia.
Inheritance of the APP mutation leads to AD with 100% pene-
trance (Goate and Hardy, 2011). Mice engineered to overexpress
mutant human APP, show memory impairment along with Aβ
deposition (Gotz and Ittner, 2008), supporting the Aβ hypothe-
sis. Electrophysiological analyses indicate an inverse correlation
between Aβ levels and the amplitude of hippocampal long-term
potentiation (LTP; Walsh etal., 2002; Westerman etal., 2002), an
underlying mechanism of memory. A recent study found that
reducing tau alleviated Aβ-induced memory impairment in APP
transgenic (Tg) mice (Roberson etal., 2007), suggesting that tau
contributes to memory impairment in APP Tg mice. However,
contrary to these results, recent clinical trials show that reducing
Aβgeneration,orremovingAβdepositsfailtohalttheprogression
of dementia (Holmes etal., 2008).
NFT FORMATION PROMOTES MEMORY IMPAIRMENT
AND DEMENTIA
ThenumberofNFTs,unliketheextentofAβdeposition,correlates
strongly with the degree of dementia (Gomez-Isla etal., 1997).
In diseased brains, synaptic and neuronal loss are prominent
in regions with detectable NFTs, implicating NFT formation in
AD associated memory impairment and dementia (Masliah etal.,
1992). Based on the observations of Braak and Braak (1990),a s
AD progresses, NFTs are observed ﬁrst in the entorhinal cortex,
a region integral to memory formation and maintenance, later
spreading into the limbic cortex and neocortex, regions asso-
ciated with emotions, and higher functioning such as thought,
respectively. Considering the role of these regions in normal brain
function, this sequential formation of NFTs could go some way
to explaining the clinical progression of AD. Before NFT for-
mation, tau is hyperphosphorylated by glycogen synthase kinase
3β (GSK-3β) activation and forms granular tau oligomers. This
hyperphosphorylated tau is associated with synapse loss (Kimura
etal.,2007),whilegranulartauoligomersareinvolvedinneuronal
death. These data imply that the neuronal dysfunction resulting
fromsynapticandneuronalloss(Kimuraetal.,2010),occurswhen
NFTs are formed.
NFT FORMATION PROMOTES NEURONAL DYSFUNCTION
Mice that overexpress P301L, a mutant form of tau, display age-
related NFTs, neuronal death, and memory deﬁcits (Ramsden
etal.,2005;Santacruzetal.,2005).Althoughinhibitingmutanttau
overexpression in these mice blocks neuronal death and improves
memory, NFTs continue to form (Ramsden etal., 2005; Spires
etal., 2006). This suggests that NFTs in themselves are not toxic,
but instead, the processes of NFT formation, neuronal death and
neuronal dysfunction underly the pathogenic mechanism.
The formation of tau ﬁbrils follows three sequential steps
(Maeda etal., 2007; Kimura etal., 2008; Takashima, 2008), and
has been studied using atomic force microscopy (AFM). AFM
allows direct observation of tau aggregation in experimental solu-
tions, with no special pretreatments, in contrast to scanning
electron microscopy which requires several pretreatment steps.
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First,hyperphosphorylatedmonomerictaubindstogethertoform
soluble oligomers. The structure of these oligomers however, is
not discernible under AFM. Second, the soluble tau oligomers
t a k eo naβ-sheet structure, forming insoluble tau aggregates.
These aggregates become granular-shaped oligomers consisting
of approximately 40 tau molecules, which are detectable under
AFM. Third and ﬁnally, the increased concentration of granu-
lar tau causes these oligomers to fuse, forming tau ﬁbrils (Maeda
etal.,2007).
As a major tau kinase,GSK-3β induces tau hyperphosphoryla-
tion,asoneof theearliesteventsinNFTformation(Ishiguroetal.,
1988, 1993). Hyperphosphorylated tau or soluble tau oligomers
are associated with loss of synapses in wild type tau Tg mice
(Kimura etal., 2007), while granular tau oligomers are associated
with loss of neurons in P301L tau Tg mice (Kimura etal., 2010).
Thus, the intermediary, soluble and granular tau oligomers can
promote synaptic and neuronal loss before NFT formation. This
suggests that rather than being the cause of cell death, NFTs rep-
resent a biological tombstone, marking the sites of neuron death.
Therefore, memory impairment probably occurs when NFTs are
seenintheentorhinalcortexandhippocampus,sincesynapticand
neuronallossoccurbeforetheformationof NFTsintheseregions.
TAU PHOSPHORYLATION BY GSK-3β
Tau protein kinase I (TPKI; Ishiguro etal., 1988), is encoded by
a nucleotide sequence identical to that of GSK-3β (Ishiguro
etal., 1993), but not GSK-3α. This kinase is activated by aggre-
gated Aβ and induces tau hyperphosphorylation as seen in NFTs
and neuron death, in hippocampal cultures (Takashima etal.,
1993, 1996). Phosphorylation of the tau Ser422 residue, a site
not phosphorylated by GSK-3β, is speciﬁcally seen in NFTs
(Morishima-Kawashima etal., 1995) indicating the involvement
of additional kinases in this process. While the Ser422 residue can
be phosphorylated by c-Jun amino-terminal kinase (JNK), this is
not enough to promote tau aggregation. In cultured cells at least,
bothJNKandGSK-3βactivationareneededtogeneratetauaggre-
gation(Satoetal.,2002). TheseresultspointtoGSK-3βactivation
as a requirement for AD pathogenesis.
Mice overexpressing GSK-3β show an accumulation of hyper-
phosphorylated tau, neuronal death in the hippocampus, and
memoryimpairmentinobjectrecognitiontests(Lucasetal.,2001;
Hernandez etal., 2002). These mice also exhibit reduced hip-
pocampal LTP (Hooper etal., 2007), and this memory deﬁcit
is reversed when tau expression stops (de Barreda etal., 2010).
Reducing tau levels (Roberson etal., 2007) and inhibiting GSK-3
(Sereno etal., 2009) can each rescue memory impairment in APP
Tg mice. Aβ activates GSK-3β, inducing tau hyperphosphoryla-
tioninhippocampalneurons,anditisthisGSK-3βactivationthat
leads to reduced LTP and eventual memory impairment in APP
Tg mice. Again,evidence shows that activation of GSK-3β i sak e y
factor in AD associated memory impairment, promoting the idea
that inhibitors of GSK-3β,may be potential therapeutic agents for
this disease.
GSK-3 INHIBITORS
Peineau etal. (2007) showed that GSK-3β localizes to postsynap-
tic regions and that GSK-3 inhibitors block NMDA-dependent
long-term depression (LTD) induction. Our own data (unpub-
lished)showsablockadeofLTDinductioninGSK-3βheterozygote
knockoutmice.AlthoughseveralcompanieshavedevelopedGSK-
3 inhibitors, there are currently no successful candidates in Phase
III trials. Lithium, a longstanding therapeutic drug used in bipo-
lar disorder (Gould etal., 2006), is a speciﬁc inhibitor for GSK-3
(KleinandMelton,1996).LithiuminhibitsGSK-3directlybycom-
peting with magnesium binding sites. It also acts indirectly, by
enhancing serine phosphorylation of GSK-3, as well as through
β-arrestin complex formation (reviewed in this Research Topic
series:Eldar-FinkelmanandMartinez,2011;FrelandandBeaulieu,
2012). Lithium treatment inhibits tau hyperphosphorylation,and
NFT formation (Engel etal., 2006; Leroy etal., 2010), alleviating
memorydeﬁcitsnotonlyinmiceoverexpressingtau,butalsomice
expressingbothAPPandPS1(Zhangetal.,2011).Thereforehypo-
thetically, lithium inhibition of GSK-3β should halt the clinical
progressionofADinhumans.Whileshort-termlithiumtreatment
failedtoimprovecognitivefunction,abiomarkerforAD(Hampel
etal., 2009), long-term treatment signiﬁcantly reduced phospho-
rylated tau levels in cerebrospinal ﬂuid, a potential biomarker for
AD,andimprovedcognitivefunction(Forlenzaetal.,2011).Inter-
estingly, a retrospective study of bipolar and unipolar-depression
patients with a history of lithium treatment, found that these
patients had a higher risk of developing dementia (Dunn etal.,
2005). It therefore appears that GSK-3 performs a dual role.
In patients without dementia, GSK-3 activity maintains cogni-
tive function, whereas patients with dementia show excessive
activation of GSK-3.
THE ROLE OF GSK-3β IN SYNAPTIC PLASTICITY
GSK-3 exists as two isoforms,α and β,which share high sequence
identity and are encoded by genes on chromosomes 19 and 3
respectively, in humans (Woodgett, 1990). GSK-3β and GSK-
3α localize to different compartments. GSK-3β, but not GSK-3α
localizes to the mitochondria and synaptosomes (Hoshi etal.,
1995). Therefore it is likely that GSK-3β may be directly involved
in synaptic plasticity, while GSK-3α may act indirectly, via the
regulation of gene expression (more details in this Research Top-
ics series, as reviewed by Beaulieu etal., 2011; Polter and Li,
2011). These isoforms share common substrates including tau,
but they also have distinct functions. While knockout of GSK α
in mice induces increased insulin sensitivity,knockout of GSK-3β
in mice is embryonically lethal (Hoeﬂich etal., 2000; MacAulay
etal.,2007).
GSK-3β is pivotal in the cascade leading to NFT formation,
which in turn drives dementia in AD. GSK-3β could be seen as a
time-delayedignitionswitchinthebrain,whichinoldagetriggers
the process of dementia. As mentioned previously,patients with a
longhistoryoflithiumtherapy,andconsequentlysuppressedlevels
of GSK-3, show a higher risk for developing dementia compared
with lithium naïve patients (Dunn etal., 2005). These observa-
tions imply that controlled levels of GSK-3 activity are required
for maintaining normal brain function, and as we already know,
excessive activation of GSK-3β, drives NFT formation, leading to
disease. Unraveling the dual role of GSK-3β requires an under-
standing of the physiological function of this protein in healthy
adultbrainsandhowthischangeswithaging.Asweknow,GSK-3β
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FIGURE 1 | Mechanism for memory formation and maintenance.
Learning stimulation leads to short-term memory, which lasts a few hours
and is converted to long-term memory through a process of consolidation.
Active memory is formed by recalling and updating long-term memory.This
updated memory becomes long-term memory through a process of
memory reconsolidation. Reconsolidation is a protein synthesis-dependent
process that is required for updating the reactivated memory and for
maintaining long-term memory.
is required for NMDA-dependent LTD induction (Peineau etal.,
2007). It is this requirement for GSK-3β in synaptic plasticity that
fuels the analysis of GSK-3β in memory formation.
GSK-3β ACTIVATION IS REQUIRED FOR MEMORY
RECONSOLIDATION
Learning stimuli ﬁrst lead to short-term memory formation,
which lasts a few hours and is then converted to long-term
memory, through a process of memory consolidation. Active
memory is formed by recalling and updating long-term mem-
ory. This updated memory becomes long-term memory through
a process of memory reconsolidation. Reconsolidation is required
for updating reactivated memory, and maintaining long-term
memory (Figure 1). Although memory consolidation and recon-
solidation are thought to have distinct molecular pathways, both
are protein synthesis-dependent (Nader etal., 2000; Riccio etal.,
2002; Eisenberg etal., 2003; Biedenkapp and Rudy, 2004; Dudai
and Eisenberg, 2004; Lee etal., 2006; Morris etal., 2006). We used
GSK-3β heterozygous knockout mice (+/−) to understand how
GSK-3β ﬁts into these pathways. While the homozygous GSK-3β
mutationisembryonicallylethal,heterozygousmiceexpressGSK-
3β at approximately 50%, and a relative activity was about 70%
of wild type mice (Kimura etal., 2008). For GSK-3α, the paralog
of GSK-3β, the total amount and relative activity of GSK-3α did
not differ between GSK-3β+/− and wild type mice. As previously
reported (Hoeﬂich etal.,2000),GSK-3β+/− mice are healthy and
fertile, with normal circadian rhythms, life span, and locomotor
activity,compared to wild type mice.
In the contextual fear conditioning paradigm, GSK-3β+/−
mice showed similar freezing times in response to unconditioned
stimuli as wild type mice,and there was no difference in the freeze
times between GSK-3β+/− andWT mice in the consolidation test
(Figure 2A; Kimura etal., 2008). This suggests no impairment in
the ability of GSK-3β+/− mice to form and consolidate memo-
ries,andthatthesememoriescanbemaintainedforatleast7days,
the time period examined in this study (Kimura etal., 2008). In
reconsolidation however, GSK-3β+/− mice, showed signiﬁcantly
lessfreezetimecomparedwithwildtypemice,atday7(Figure2B;
Kimura etal., 2008). These results indicate that GSK-3β
FIGURE 2 | (A) Deﬁciencies in GSK-3β do not affect the process of
memory consolidation. Mice were placed in a novel environment for 5 min
(CS) and then subjected to three sequential foot-shocks (US). On day 7
after conditioning, animals were placed in the original environment, without
shocks, for 5 min.The freezing time was recorded for these animals.
(B) Deﬁciencies in GSK-3β impair memory reconsolidation. Mice were
placed in the environmental for 5 min (CS), and then subjected to three
sequential foot-shocks (US). One day after conditioning, animals were
exposed to the same environment for 5 min. Six days after their ﬁrst
exposure to conditioning, animals were re-exposed again and the freezing
time was recorded.
heterozygotes are capable of learning and stabilizing long-term
memory for 7 days, if memory is not reactivated. However, GSK-
3β+/− mice failed to achieve reconsolidation when memory was
reactivated once before testing (Kimura etal., 2008). The retro-
gradeamnesiaexhibitedbythesemiceinthereconsolidationtestof
contextualfearconditioning,pointstopossibleimpairedmemory
reconsolidation,inkeepingwiththetheorythatGSK-3βactivation
is required for memory reconsolidation or maintenance.
PROSPECTIVE ROLE OF GSK-3β IN BRAIN AGING
GSK-3β is involved in NMDA-dependent LTD induction and
memory reconsolidation (Peineau etal., 2007; also reviewed in
this Research Topic series by Bradley etal., 2012). However, the
relationship between LTD induction and memory reconsolida-
tion is unclear, although there are reports that LTD is important
for memory formation or new object recognition. Focusing on
synapticplasticity,particularlyLTP,geneticablationof theNMDA
receptor impaired place learning in a LTD dependent manner
(Tsienetal.,1996).FurtheranalysisusingCaMKIVknockoutmice
indicates that late LTP is involved in the consolidation process of
memory formation (Kang etal., 2001). Thus, both LTP and LTD
contribute to memory formation, in which the memory consoli-
dation processes may preferentially depend on LTP, and memory
reconsolidation processes require LTD. In memory reconsolida-
tion, LTD maintains a prior potentiated circuit by competitive
synaptic maintenance (Diamond etal., 2005) and protects stable
memory traces. This may explain why activation of GSK-3β is
required in reconsolidation but not in consolidation processes in
normal brain function. GSK-3β activation in the entorhinal cor-
tex and hippocampus is required for spatial recognition, in aged
but not young brains (unpublished result). While this process is
required for maintaining normal brain function in old age, the
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frequentactivationof GSK-3βinducesNFTsintheentorhinalcor-
tex (Braak and Braak,1996) and hippocampus. It would therefore
appear that GSK-3β activation is an early event in normal brain
aging as well as AD.
We put forward that, generally, as we age, we learn and accu-
mulate many memories. When we are confronted with a new idea
or task, we draw on our experiences, that is, we recall related
memories to help us understand new information. The frequent
needtorecallandreconsolidatememoriesreliesonincreasedacti-
vation of GSK-3β and consequently, tau phosphorylation. Over
time, NFTs accumulate in the entorhinal cortex, which is a very
early pathological change in sporadic AD.
CONCLUSION
Tau hyperphosphorylation and NFT formation are early fea-
tures of dementia associated with AD. This major change in the
phosphorylation state of tau leads to deposition of pathological
tau in NFTs, and these tangles are formed in a speciﬁc spatial and
temporal pattern within the brain. It is the formation rather than
the presence of these NFTs that induces neuronal dysfunction and
death, leading to tauopathies.
GSK-3β is a major kinase for tau phosphorylation associated
with both physiological brain function and AD pathophysiol-
ogy. GSK-3β is also required for synaptic plasticity. Reduced
GSK-3 expression in GSK-3β+/− mice results in impaired mem-
ory reconsolidation emphasizing the importance of GSK-3 in
promoting memory maintenance via reconsolidation. A greater
understanding of how synaptic plasticity changes with aging,
through the analysis of AD-related molecules such as GSK-3β and
tau, would provide a solid platform of knowledge, from which
new therapeutic targets and innovative agents could be developed
for AD.
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